Wesana Health has announced that following the completion of a successful Pre-IND meeting with the U.S. Food and Drug Administration (FDA), the company is exploring the opportunity to expand its lead indication for SANA-013 to major depressive disorder (MDD) following the completion of a non-brokered private placement by the company.
Category Press Release
Published in Financial Post
Companies Featured
Wesana HealthWesana Health is a data-driven life science company focused on the delivery and development of therapies, including psychedelics, to treat traumatic brain injury (TBI), migraines, depression and anxiety.